Bacil Pharma loses another big holder — Patel cuts stake by 7.10%
Nikita Hiren Patel sold nearly a third of her remaining stake, dropping from 17.17% to 10.07%. The ₹60-cr nano-cap has zero operating revenue.
— 6 earlier stories on Bacil Pharma Ltd. →What's new
- Nikita Hiren Patel sold 7.10% equity on June 22-23, reducing her stake to 10.07%
- This is her second sale this month: she sold 2.27% earlier in June
- The sales come amid zero operating revenue and a ₹60 cr market cap
Why this matters
A substantial shareholder exiting nearly half her stake in two transactions within weeks signals waning conviction in a company with no revenue. For a ₹60-cr nano-cap, this volume of selling can skew the stock price and raise questions about the remaining holders' commitment.
What we're watching
- Whether Patel sells further; she remains a 10% holder and could cross below the material threshold
- Bacil's board meets June 26 to discuss fundraising — any clarity on use of funds could matter
- Market reaction: another large holder's exit after a 5.57% sale on June 13
The full read
Nikita Hiren Patel, a substantial non-promoter shareholder in Bacil Pharma, has sold 7.10% of the company in two days, June 22–23. That follows an earlier 2.27% sale this month. Her stake now stands at 10.07%, down from 17.17%. The ₹60-cr nano-cap has zero operating revenue and net profit of just ₹1 crore from other income in the March 2026 quarter. The selling comes after a 5.57% exit by another large holder on June 13 and a week after promoters proposed an R&D arm, a plan that lacks detail for a company with no sales. Patel's rapid exits look less like rebalancing and more like an exit. The board meets June 26 to discuss fundraising; what that money would be used for is the open question. Until then, every large sale at Bacil is a signal, not a noise.
Questions answered
- Who sold the stake in Bacil Pharma?
- Nikita Hiren Patel, a non-promoter substantial shareholder, sold 7.10% equity on June 22–23, reducing her holding from 17.17% to 10.07%.
- How much has Patel sold in total this month?
- She sold 2.27% earlier in June and 7.10% now, a combined stake reduction of nearly 9.37% in June.
- What is Bacil Pharma's financial condition?
- Bacil has a market cap of ₹60 crore and reported zero operating revenue in its latest March 2026 quarter. Net profit was ₹1 crore from other income.
- Why does this stake sale matter?
- The rapid exit by a key non-promoter holder follows a 5.57% sale by another shareholder on June 13. For a non-revenue company, such concentrated selling suggests diminishing confidence and could pressure the stock.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 24 Jun 2026 · 10:37 AM IST Bacil Pharma loses another big holder — Patel cuts stake by 7.10%
- 1d ago Bacil Pharma board to mull fundraising options on June 26
- 6d ago Bacil Pharma proposes R&D arm, but numbers are missing
- 11d ago Another large Bacil Pharma shareholder sells 5.57% stake
- 13d ago Nikita Patel cuts Bacil Pharma stake to 17% in open-market sale